| Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report M Brunet, T Van Gelder, A Åsberg, V Haufroid, DA Hesselink, L Langman, ... Therapeutic drug monitoring 41 (3), 261-307, 2019 | 525 | 2019 |
| Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer Y Togashi, K Masago, S Masuda, T Mizuno, M Fukudo, Y Ikemi, ... Cancer chemotherapy and pharmacology 70, 399-405, 2012 | 295 | 2012 |
| Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin M Tsuda, T Terada, T Mizuno, T Katsura, J Shimakura, K Inui Molecular pharmacology 75 (6), 1280-1286, 2009 | 217 | 2009 |
| Human ontogeny of drug transporters: review and recommendations of the pediatric transporter working group KLR Brouwer, LM Aleksunes, B Brandys, GP Giacoia, G Knipp, ... Clinical Pharmacology & Therapeutics 98 (3), 266-287, 2015 | 180 | 2015 |
| Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology S Bergan, M Brunet, DA Hesselink, KL Johnson-Davis, PK Kunicki, ... Therapeutic drug monitoring 43 (2), 150-200, 2021 | 119 | 2021 |
| Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics T Mizuno, M Fukudo, T Terada, T Kamba, E Nakamura, O Ogawa, K Inui, ... Drug metabolism and pharmacokinetics 27 (6), 631-639, 2012 | 114 | 2012 |
| OCT1 genetic variants influence the pharmacokinetics of morphine in children T Fukuda, V Chidambaran, T Mizuno, R Venkatasubramanian, ... Pharmacogenomics 14 (10), 1141-1151, 2013 | 110 | 2013 |
| Exposure–toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma M Fukudo, T Ito, T Mizuno, K Shinsako, E Hatano, S Uemoto, T Kamba, ... Clinical pharmacokinetics 53, 185-196, 2014 | 102 | 2014 |
| ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children R Venkatasubramanian, T Fukuda, J Niu, T Mizuno, V Chidambaran, ... Pharmacogenomics 15 (10), 1297-1309, 2014 | 87 | 2014 |
| Developmental pharmacokinetics of sirolimus: implications for precision dosing in neonates and infants with complicated vascular anomalies T Mizuno, T Fukuda, C Emoto, PS Mobberley‐Schuman, AM Hammill, ... Pediatric blood & cancer 64 (8), e26470, 2017 | 72 | 2017 |
| ABCG2 421C> A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma T Mizuno, T Terada, T Kamba, M Fukudo, T Katsura, E Nakamura, ... Annals of oncology 21 (6), 1382-1383, 2010 | 69 | 2010 |
| A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a … NJ Ullrich, SP Prabhu, AT Reddy, MJ Fisher, R Packer, S Goldman, ... Neuro-oncology 22 (10), 1527-1535, 2020 | 65 | 2020 |
| Dual imaging of pulmonary delivery and gene expression of dry powder inhalant by fluorescence and bioluminescence T Mizuno, K Mohri, S Nasu, K Danjo, H Okamoto Journal of controlled release 134 (2), 149-154, 2009 | 65 | 2009 |
| Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia PT McGann, O Niss, M Dong, A Marahatta, TA Howard, T Mizuno, A Lane, ... American journal of hematology 94 (8), 871-879, 2019 | 61 | 2019 |
| Pharmacokinetics of oral methadone in the treatment of neonatal abstinence syndrome: a pilot study JR Wiles, B Isemann, T Mizuno, ME Tabangin, LP Ward, H Akinbi, ... The Journal of pediatrics 167 (6), 1214-1220. e3, 2015 | 56 | 2015 |
| Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies T Mizuno, C Emoto, T Fukuda, AM Hammill, DM Adams, AA Vinks European Journal of Pharmaceutical Sciences 109, S124-S131, 2017 | 54 | 2017 |
| Real‐world infliximab pharmacokinetic study informs an electronic health record‐embedded dashboard to guide precision dosing in children with Crohn’s disease Y Xiong, T Mizuno, R Colman, J Hyams, JD Noe, B Boyle, YT Tsai, ... Clinical Pharmacology & Therapeutics 109 (6), 1639-1647, 2021 | 53 | 2021 |
| OCT1 genetic variants are associated with postoperative morphine-related adverse effects in children R Balyan, X Zhang, V Chidambaran, LJ Martin, T Mizuno, T Fukuda, ... Pharmacogenomics 18 (7), 621-629, 2017 | 50 | 2017 |
| Influence of OCT 1 ontogeny and genetic variation on morphine disposition in critically ill neonates: lessons from PBPK modeling and clinical study D Hahn, C Emoto, JC Euteneuer, T Mizuno, AA Vinks, T Fukuda Clinical Pharmacology & Therapeutics 105 (3), 761-768, 2019 | 48 | 2019 |
| Development of a pharmacokinetic‐guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia M Dong, PT McGann, T Mizuno, RE Ware, AA Vinks British journal of clinical pharmacology 81 (4), 742-752, 2016 | 47 | 2016 |
